Predictions On The Upcoming Quarterly, page-27

Hi Plovagurl,
I looked at the ASX co-authored, Code for Best Practice for Reporting by Life Science Companies, 2nd ed. It states:
Reporting during the trial
Significant changes to a clinical trial
program can have a considerable
impact on market value and should
be announced to the market as soon
as possible after they are identified.
These may include a change to the
endpoints of the trial, a significant
delay in its progress, or an inability to
recruit adequate numbers of patients
affecting the statistical significance of
the trial in meeting its endpoints.
Regular reporting of the progress
of clinical trials including the
recruitment process is encouraged
but companies need to be careful not
to give a misleading impression of
the significance of events during the
conduct of the trial.